<DOC>
	<DOCNO>NCT02698410</DOCNO>
	<brief_summary>The purpose protocol evaluate efficacy safety Lanreotide ATG 120 mg combination Temozolomide subject unresectable advanced neuroendocrine tumour lung thymus Disease Control Rate 9 month .</brief_summary>
	<brief_title>Efficacy Safety Lanreotide Autogel ( ATG ) Combination With Temozolomide Subjects With Thoracic Neuroendocrine Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Histological document unresectable advanced ( locally metastatic ) well moderately differentiate neuroendocrine tumor lung thymus ( typical atypical carcinoid accord World Health Organisation ( WHO ) 2004 criterion ) ; Imaging document progression within 12 month screen visit ( V1 ) , accord RECIST criterion v 1.1 ; Measurable disease , define RECIST criterion v 1.1 , CT scan perform screen visit ( V1 ) ; Octreoscan Ga68DOTATATE/TOC/NOCPETTC within 12 month screen visit ( V1 ) ; Adequate liver , renal bone marrow function . Poorly differentiated neuroendocrine carcinoma mixed Neuroendocrine tumour ( NET ) , accord WHO 2004 criterion . Neuroendocrine tumours lung thymus . Nonneuroendocrine thymic neoplasm . Treated systemic therapy ( chemotherapy , interferonalpha , somatostatin analogue , molecular target therapy ) within 1 month prior screen visit ( V1 ) . Treated number systemic therapy line &gt; 3 prior screen visit ( V1 ) , follow : 1. chemotherapy 1 line prior V1 ; 2. somatostatin analogue 1 line therapy , consider treatment last 6 month , prior V1 ; 3. therapy Temozolomide ( TMZ ) prior V1 . Received prior therapy Peptide Receptor Radionuclide Therapy ( PRRT ) within 6 month prior screen visit ( V1 ) . Received locoregional therapy ( Transarterial embolization , Transcatheter arterial chemoembolization , thermoablation radiofrequency ) Selective internal radiotherapy within 3 month prior screen visit ( V1 ) . Presence symptomatic brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>